A Pituitary Society update to acromegaly management guidelines

M Fleseriu, BMK Biller, PU Freda, MR Gadelha, A Giustina, L Katznelson, ME Molitch, SL Samson, CJ Strasburger, AJ (Aart-Jan) van der Lely, S Melmed

Research output: Contribution to journalArticleAcademicpeer-review

154 Citations (Scopus)

Abstract

Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalPituitary
Volume24
Issue number1
DOIs
Publication statusPublished - Feb 2021

Bibliographical note

Funding Information:
Development of this guideline update was supported by the Pituitary Society. No entity provided financial support.

Funding Information:
MF is a scientific consultant for Chiasma, Crinetics, Ipsen, Ionis, Novartis, Pfizer and Recordati and is a principal investigator with support to the institution for Chiasma, Crinetics, Ionis, and Novartis. BMKB is principal investigator of research support to the institution from Crinetics, Ionis, and Novartis, and received occasional consulting honoraria from Chiasma, Crinetics, and Novartis. PUF has received research grants to the institution for clinical research studies from Pfizer, Novartis, Ipsen, and Chiasma. MRG has served as principal investigator in clinical trials supported by Novartis and Crinetics, has served on advisory boards for Novartis and Crinetics, and served as a speaker for Novatis and Ipsen. AG is consultant for Chiasma, Genevant, Ipsen, Pfizer, and Recordati and received research grants from Ipsen, Novartis, and Pfizer to the institution. LK has received research support from Novartis and Chiasma, and has served as an advisor to Chiasma, Ionis, and Pfizer. MEM has research support from Chiasma, Novartis, Ionis, and Crinetics. SLS has served as an advisor and/or investigator for Novartis, Chiasma, Pfizer, and Ipsen, and has received investigator-initiated funding from Novartis. CJS served as an advisor to and received speaker’s fees from Pfizer, Ipsen, Chiasma, and Crinetics. AJVD served as an advisor to and received speaker’s fees from Pfizer, Ipsen, Amolyt, Tiburio, and Crinetics. SM is a consultant for Chiasma, Crinetics, Ionis, and Ipsen, and received a research grant from Pfizer to the institution.

Publisher Copyright:
© 2020, The Author(s).

Research programs

  • EMC OR-01

Fingerprint

Dive into the research topics of 'A Pituitary Society update to acromegaly management guidelines'. Together they form a unique fingerprint.

Cite this